Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management
Marco Caminati, Bianca Olivieri, Annarita Dama, et al.
Expert Review of Respiratory Medicine (2022) Vol. 16, Iss. 7, pp. 713-721
Closed Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023
W.J. Fokkens, A-S Viskens, V. Backer, et al.
Rhinology Journal (2023)
Open Access | Times Cited: 157
Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months
Rik Johannes Leonardus van der Lans, Josje Janna Otten, Gwijde Flavius Jacobus Petrus Maria Adriaensen, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2684-2697
Open Access | Times Cited: 39
Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study
B. Molina, Roberto Padoan, Maria Letizia Urban, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 12, pp. 1587-1593
Closed Access | Times Cited: 28
Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks
Teppei Hagino, Risa Hamada, Mai Yoshida, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 11
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Paola Maria Cutroneo, Elena Arzenton, Fabiana Furci, et al.
BioDrugs (2024) Vol. 38, Iss. 3, pp. 425-448
Open Access | Times Cited: 10
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature
Marella Reale, Giuseppe Licci, Pietro Orlando, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 10, pp. 5023-5031
Closed Access | Times Cited: 9
Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan
Teppei Hagino, Akihiko Uchiyama, Marina Onda, et al.
Dermatitis (2025)
Closed Access | Times Cited: 1
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Mu Xian, Bing Yan, Xicheng Song, et al.
Allergy (2025)
Open Access | Times Cited: 1
Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Fabio S. Ryser, Ayla Yalamanoglu, Alan Valaperti, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2712-2723
Open Access | Times Cited: 18
Eosinophils—from cradle to grave
Miloš Jeseňák, Zuzana Diamant, Dagmar Simon, et al.
Allergy (2023) Vol. 78, Iss. 12, pp. 3077-3102
Open Access | Times Cited: 18
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence
Marco Caminati, Claudio Micheletto, Francesca Norelli, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 15-23
Closed Access | Times Cited: 7
Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years
Patrick Huber, Ulrike Förster‐Ruhrmann, Heidi Olze, et al.
Allergy (2024) Vol. 79, Iss. 11, pp. 3108-3117
Open Access | Times Cited: 6
Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, et al.
Journal of Immunology Research (2023) Vol. 2023, pp. 1-10
Open Access | Times Cited: 13
Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis
Xiaoying Chen, Haopeng Zhi, Xiaohu Wang, et al.
Lung (2024) Vol. 202, Iss. 4, pp. 367-383
Closed Access | Times Cited: 5
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis
Celeste M. Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
JAMA Dermatology (2024) Vol. 160, Iss. 10, pp. 1044-1044
Closed Access | Times Cited: 5
Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
Giovanna Piazzetta, Nadia Lobello, Emanuela Chiarella, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1404-1404
Open Access | Times Cited: 12
Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group
Marco Caminati, Angelo Fassio, Federico Alberici, et al.
Allergy (2023) Vol. 79, Iss. 2, pp. 516-519
Open Access | Times Cited: 12
Combination of Biological Therapy in Severe Asthma: Where We Are?
Lorenzo Carriera, Marta Fantò, Alessia Martini, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 11, pp. 1594-1594
Open Access | Times Cited: 12
Postmarketing Analysis of Eosinophilic Adverse Reactions in the use of Biologic Therapies for Type 2 Inflammatory Conditions
Dafna Gershnabel Milk, Kent Lam, Joseph K. Han
American Journal of Rhinology and Allergy (2024)
Closed Access | Times Cited: 4
Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab
Andrea Ciofalo, Antonella Loperfido, Silvia Baroncelli, et al.
European Archives of Oto-Rhino-Laryngology (2024)
Closed Access | Times Cited: 4
Real-world Management of COPD: Dupilumab's Role in Targeting T2 Inflammation as a Treatable Trait
Miguel Jiménez-Gómez, Rocío Magdalena Díaz-Campos, Marta Padilla-Bernáldez, et al.
Archivos de Bronconeumología (2025)
Closed Access
AP2M1 as the potential biomarker for prediction of the response of atopic dermatitis to Dupilumab therapy: Multi-omics analysis and evidence
Shixiong Peng, Wenjie Yan, Yan Yang, et al.
International Journal of Biological Macromolecules (2025), pp. 139757-139757
Closed Access
Biological therapy in Chronic rhinosinusitis with nasal polyps
Zeyi Jin, Bing Yan, Luo Zhang, et al.
Expert Review of Clinical Immunology (2025)
Closed Access
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment
Valentina D’Aiuto, Ilaria Mormile, Francescopaolo Granata, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1729-1729
Open Access
Page 1 - Next Page

Scroll to top